<DOC>
	<DOCNO>NCT02177760</DOCNO>
	<brief_summary>Study Design : SCID infant receive unconditioned haploidentical transplant start Sirolimus ( 0.05 mg/kg/day ) day -5 Acute Graft-Versus-Host Disease ( aGVHD ) prophylaxis . Sirolimus level monitor goal sirolimus trough level 5-8 ng/mL . Patients monitor sign aGVHD define UCSF SOP CL 221.06 day +100 . Sirolimus taper T-regulatory cell CD4 effector cell ratio &gt; = 9 % . Setting : Inpatient BMT Unit Benioff Children 's Hospital UCSF Medical Center Study Subjects : 15 infant diagnosis maternally engraft T cell SCID CA Newborn screen receive unconditioned haploidentical HSCT Main Outcome Measures : Incidence aGVHD ( dermatitis , hepatitis , enteritis ) define SOP CL 221.06 Day +100 . Hypothesis 1 . Patients place sirolimus prophylaxis low incidence aGVHD compare historical control . Hypothesis 2 . Lower dos sirolimus milligram per kilogram require maintain goal trough 5-8 ng/mL .</brief_summary>
	<brief_title>Sirolimus Prophylaxis aGVHD TME SCID</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Infants diagnose SCID CA newborn screen Evidence Maternal Engraftment Unconditioned haploidentical hematopoeitic stem cell transplant Evidence acute graft vs. host disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>SCID</keyword>
	<keyword>severe combine immunodeficiency</keyword>
	<keyword>maternal engraftment</keyword>
	<keyword>aGVHD prophylaxis</keyword>
	<keyword>sirolimus</keyword>
</DOC>